object
aim
assess
effect
amoxicillin
treatment
adult
patient
present
primari
care
lower
respiratori
tract
infect
lrti
infect
potenti
bacteri
viral
mix
bacterialvir
infect
method
multicentr
random
control
trial
focus
adult
lrti
suspect
pneumonia
patient
random
receiv
either
antibiot
amoxicillin
g
placebo
three
time
daili
consecut
day
use
computergener
random
number
followup
day
secondari
analysi
trial
symptom
durat
primari
outcom
symptom
sever
score
ill
deterior
reconsult
new
worsen
symptom
hospit
admiss
analys
prespecifi
subgroup
use
regress
model
subgroup
interest
patient
strictli
bacteri
strictli
viral
combin
infect
patient
elev
valu
procalcitonin
creactiv
protein
blood
urea
nitrogen
result
patient
amoxicillin
n
placebo
n
random
treatment
affect
symptom
durat
n
patient
bacteri
pathogen
isol
n
benefit
amoxicillin
symptom
sever
n
reduc
point
ci
odd
ill
deterior
n
ci
time
lower
treatment
amoxicillin
bacteri
viral
pathogen
isol
combin
infect
n
conclus
amoxicillin
may
reduc
risk
ill
deterior
patient
combin
bacteri
viral
infect
found
clinic
meaning
benefit
amoxicillin
treatment
subgroup
r
bruyndonckx
clin
microbiol
infect
acut
lower
respiratori
tract
infect
lrti
common
primari
care
antibiot
treatment
limit
benefit
overal
subgroup
higher
risk
advers
cours
nevertheless
antibiot
prescrib
patient
lrti
primari
analysi
largest
trial
date
genom
combat
resist
antibiot
communityacquir
lrti
grace
http
wwwgracelrtiorg
random
placebo
control
trial
rct
found
clear
evid
clinic
meaning
benefit
treatment
amoxicillin
followup
analysi
examin
benefit
amoxicillin
clinic
defin
subgroup
patient
lrti
like
prescrib
antibiot
ie
patient
green
sputum
signific
comorbid
found
clear
evid
meaning
benefit
amoxicillin
even
subgroup
patient
evid
pneumonia
chest
xray
benefit
amoxicillin
treatment
howev
unclear
whether
patient
infect
bacteri
pathogen
might
select
benefit
antibiot
treatment
fill
evid
gap
could
help
better
target
antibiot
prescrib
primari
care
secondari
analysi
grace
rct
therefor
aim
assess
whether
patient
potenti
bacteri
pathogen
isol
receiv
benefit
amoxicillin
treatment
addit
aim
assess
whether
isol
viral
pathogen
high
level
creactiv
protein
crp
blood
urea
nitrogen
bun
procalcitonin
pct
associ
benefit
treatment
amoxicillin
detail
grace
rct
describ
detail
elsewher
summari
nonpregn
adult
present
primari
care
acut
cough
pneumonia
suspect
recruit
novemb
april
primari
care
physician
network
across
european
countri
belgium
england
franc
germani
itali
netherland
poland
spain
slovakia
slovenia
sweden
wale
patient
consum
antibiot
month
consult
random
receiv
either
antibiot
amoxicillin
g
placebo
three
time
daili
consecut
day
patient
ask
complet
symptom
diari
daili
symptom
settl
maximum
day
diari
record
sever
cough
phlegm
short
breath
wheez
runni
nose
chest
pain
muscl
ach
headach
disturb
sleep
feel
unwel
fever
interfer
daili
activ
symptom
score
scale
normalnot
affect
littl
problem
slight
problem
moder
bad
bad
bad
bad
could
patient
nasopharyng
swab
taken
day
present
sampl
analys
use
bacteri
viral
polymeras
chain
reaction
analysi
test
bacteri
pathogen
streptococcu
pneumonia
haemophilu
influenza
mycoplasma
pneumonia
chlamydia
pneumonia
bordetella
pertussi
legionella
pneumonia
viral
pathogen
rhinoviru
influenza
viru
coronaviru
respiratori
syncyti
viru
human
metapneumoviru
parainfluenza
viru
adenoviru
polyomaviru
bocaviru
sampl
pathogen
present
either
bacteri
viral
refer
confirm
infect
sampl
bacteri
pathogen
detect
refer
bacteri
infect
viral
pathogen
present
sampl
refer
pure
bacteri
infect
sampl
viral
pathogen
detect
refer
viral
infect
bacteri
pathogen
present
sampl
refer
pure
viral
infect
sampl
bacteri
viral
pathogen
detect
refer
combin
infect
note
categor
mutual
exclus
within
hour
present
gp
venou
blood
sampl
obtain
crp
bun
measur
use
convent
immunoturbidimetr
method
pct
measur
use
rapid
sensit
assay
defin
elev
crp
pct
bun
top
measur
patient
popul
refer
high
crp
high
pct
high
bun
respect
symptom
durat
primari
outcom
durat
symptom
rate
moder
bad
wors
patient
score
follow
initi
present
day
symptom
sever
secondari
outcom
symptom
sever
calcul
mean
diari
score
symptom
day
rate
patient
time
frame
select
day
antibiot
littl
chanc
provid
benefit
day
overal
symptom
sever
less
moder
bad
ill
deterior
addit
secondari
outcom
ill
deterior
defin
return
physician
worsen
symptom
new
symptom
new
sign
ill
requir
admiss
hospit
within
week
initi
consult
document
note
review
fit
cox
regress
model
symptom
durat
allow
censor
linear
regress
model
symptom
sever
logist
regress
model
ill
deterior
analys
control
sever
symptom
baselin
includ
interact
term
particular
subgroup
studi
subgroup
treatment
amoxicillin
placebo
interact
term
use
assess
whether
effect
amoxicillin
treatment
vari
subgroup
similar
model
exclud
interact
term
fit
patient
select
subgroup
subgroup
interest
patient
confirm
bacteri
pure
bacteri
viral
pure
viral
combin
infect
also
interest
subgroup
high
crp
high
bun
high
pct
subgroup
mutual
exclus
studi
approv
ethic
committe
particip
countri
compet
author
countri
also
gave
approv
patient
fulfil
inclus
criteria
given
written
verbal
inform
studi
provid
written
inform
consent
grace
rct
regist
eudract
ukcrn
portfolio
id
isrctn
fwo
total
patient
consum
antibiot
month
consult
random
symptom
durat
symptom
sever
report
patient
respect
ill
deterior
deterior
document
experienc
ill
deterior
vast
major
ill
deterior
repres
reconsult
new
worsen
symptom
sampl
size
inform
subgroup
analys
present
fig
subgroup
identifi
significantli
like
benefit
amoxicillin
durat
symptom
day
rate
moder
bad
wors
tabl
patient
pure
bacteri
infect
benefit
amoxicillin
treatment
tabl
interact
term
ci
mean
symptom
sever
score
ci
point
lower
compar
patient
placebo
tabl
patient
bacteri
infect
benefit
amoxicillin
term
ill
deterior
tabl
interact
term
ci
ci
patient
combin
infect
treat
amoxicillin
less
like
experi
ill
deterior
tabl
interact
term
ci
ci
ci
patient
receiv
placebo
experienc
ill
deterior
compar
ci
patient
receiv
amoxicillin
fig
found
clear
evid
clinic
meaning
benefit
term
symptom
durat
amoxicillin
treatment
patent
consult
primari
care
lrti
isol
potenti
bacteri
pathogen
viral
pathogen
identifi
mix
viralbacteri
infect
howev
amoxicillin
treatment
reduc
symptom
sever
among
patient
pure
bacteri
infect
reduc
risk
ill
deterior
patient
combin
infect
effect
seen
among
pure
bacteri
infect
previou
analys
grace
trial
amoxicillin
versu
placebo
patient
present
acut
lrti
primari
care
found
amoxicillin
provid
littl
benefit
overal
patient
age
fact
amoxicillin
treatment
even
associ
slight
harm
patient
experienc
side
effect
prevent
experienc
ill
deterior
secondari
subgroup
analysi
found
patient
signific
comorbid
mostli
asthma
chronic
obstruct
pulmonari
diseas
benefit
amoxicillin
treatment
term
reduc
symptom
sever
day
first
consult
primari
care
howev
benefit
term
symptom
durat
odd
ill
deterior
suggest
question
clinic
signific
modest
statist
shortterm
benefit
amoxicillin
treatment
subgroup
secondari
subgroup
analysi
present
found
patient
pure
bacteri
infect
benefit
amoxicillin
term
reduc
symptom
sever
patient
combin
infect
benefit
amoxicillin
term
reduc
chanc
ill
deterior
although
benefit
amoxicillin
treatment
infect
potenti
bacteri
pathogen
question
clinic
signific
borderlin
statist
signific
effect
combin
infect
group
almost
reduct
probabl
ill
deterior
found
clear
evid
benefit
pvalu
amoxicillin
treatment
group
patient
bacteri
infect
given
amoxicillin
treatment
averag
ineffect
patient
pure
bacteri
infect
effect
antibiot
patient
bacteri
infect
driven
effect
patient
combin
infect
assum
effect
result
chanc
may
biolog
plausibl
viral
infect
may
predispos
secondari
bacteri
infect
caus
mucos
damag
inflamm
lead
longer
sever
ill
cours
thu
make
patient
like
benefit
amoxicillin
howev
number
patient
combin
infect
could
potenti
benefit
antibiot
treatment
indic
clinic
impact
develop
predict
rule
point
care
test
patient
limit
patient
would
test
rang
bacteri
viral
diagnost
test
identifi
five
combin
infect
would
treat
one
individu
benefit
would
polici
need
shown
costeffect
short
term
potenti
medic
ill
signal
popul
peopl
lrti
need
test
would
consid
neither
symptom
durat
symptom
sever
clearli
affect
amoxicillin
treatment
odd
ill
deterior
influenc
amoxicillin
treatment
specif
subgroup
potenti
benefit
amoxicillin
treatment
therefor
balanc
side
effect
diarrhoea
nausea
skin
rash
longterm
risk
antibiot
resist
thu
patient
probabl
prescrib
antibiot
andor
clinician
could
consid
use
delay
antibiot
prescript
avoid
inappropri
use
antibiot
nevertheless
import
awar
potenti
harm
caus
undertreat
combin
infect
patient
must
given
clear
advic
reconsult
find
studi
applic
european
primari
care
clinic
practic
patient
recruit
took
place
network
across
european
countri
subgroup
studi
small
increas
risk
type
ii
error
subgroup
combin
bacteri
viral
infect
also
specifi
advanc
increas
risk
fals
posit
result
type
error
multipl
comparison
thu
result
interpret
caution
similarli
impact
amoxicillin
symptom
sever
among
patient
pure
bacteri
infect
borderlin
signific
also
doubt
clinic
import
contrast
impact
amoxicillin
treatment
reduc
risk
ill
deterior
patient
bacteri
infect
patient
combin
infect
highli
statist
signific
found
clear
evid
benefit
amoxicillin
treatment
adult
present
primari
care
lrti
symptom
sever
durat
irrespect
aetiolog
biomark
test
result
amoxicillin
treatment
reduc
risk
ill
deterior
viral
bacteri
pathogen
isol
howev
point
care
test
target
antibiot
prescrib
combin
bacteri
viral
infect
unlik
costeffect
